PCN42 A SENSITIVITY ANALYSIS ON THE COST UTILITY OF BEVACIZUMAB, CAPECITABINE, AND OXALIPLATIN COMPARED WITH FOLFOX FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER (CRC): A UK PERSPECTIVE  by Ducournau, P et al.
years) was used; after 8 years, patients were assumed to only be
at risk for death. Costs and outcomes were discounted at 3.5%
per annum. Sensitivity analyses were performed to identify inﬂu-
ential parameters in the model. RESULTS: Undiscounted mean
life expectancy for patients treated with FOLFOX4 was esti-
mated at 15.9 years. Assuming the addition of bevacizumab
reduces the risk of relapse by 23% in the ﬁrst 3 years after
surgery, as described in the protocol, and by 10% in the follow-
ing 5 years, mean survival was estimated to increase to 18.1 years
(10.8 to 12.1 years when discounted). The discounted ICER was
£19,939/life year gained. Sensitivity analysis showed that
assumptions relating to the magnitude of the relapse risk reduc-
tion and the duration of risk reduction were the most critical
determinants of the ICER. CONCLUSIONS: Addition of beva-
cizumab to FOLFOX4, the current standard regimen for patients
with stage III colon carcinoma, is expected to improve clinical
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OBJECTIVES: The purpose of this study is to estimate the
cost-effectiveness (CE) of 1-year trastuzumab treatment versus
standard care (observation following standard adjuvant chemo-
therapy) in early stage breast cancer (eBC) patients in Portugal.
METHODS: A 5-state Markov model with annual transition
cycles was developed to estimate the long term health and eco-
nomic outcomes of eBC patients based on HERA clinical trial
results. The model included the following health states: disease
free survival, recurrence, metastasis, cardiac events and death.
The model assumes a hypothetical patient cohort similar to those
of HERA study. The evaluation assumes both the health care
payer and societal perspectives. Portuguese NHS resource use
and costs were estimated from a consensus experts panel and
published unit costs, respectively, including cancer therapy costs,
adverse cardiovascular events treatment costs, disease diagnosis
and management costs and indirect costs (time off of work).
Outcomes were discounted at 3% per annum. One-way sensitiv-
ity analysis was performed on the discount rate, quality of life
estimates and non-trastuzumab treatment costs. RESULTS:
Treatment with trastuzumab was estimated to increase dis-
counted life expectancy by 2.11 in years (14.95 vs 12,84) and
quality-adjusted life expectancy by 2.01 QALYs compared to
standard care. Direct and indirect costs were projected to be
€61.839 and €19,759 with trastuzumab and €40,559 and
€25.391 with standard of care. These results corresponded to
ICERs of €10,067 and €10,595 assuming direct costs only and of
€7789 and €7400 including indirect costs, per life year gained
(LYG) and per QALY gained, respectively. CONCLUSIONS: The
1-year trastuzumab use as adjuvant therapy in HER-2 positive
eBC patients improves survival and can be considered a cost
effective therapy with a high degree of certainty in the Portuguese
setting.
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OBJECTIVES: To obtain a Dutch cost-effectiveness estimate of
trastuzumab in early breast cancer, based on a previous UK
model-based cost-effectiveness analysis. Trastuzumab is a
humanized monoclonal antibody against the HER2-receptor
extracellular domain. METHODS: Following the model trans-
ferability assessment, required adjustments were made. In a
Markov cohort model, 1 year adjuvant trastuzumab therapy was
compared to observation. Model outcomes are life years,
quality-adjusted life years (QALYs), health care costs, and cost
of productivity loss. The cycle length is one year, the time
horizon is lifetime. UK prices were replaced by updated Dutch
unit prices. Clinical input data originated from the HERA-trial;
health utilities were obtained from literature. The impact of
parameter uncertainty was assessed using age subgroup analyses,
one-way sensitivity analyses and probabilistic sensitivity analy-
sis. Subsequently, we conducted expected value of perfect infor-
mation analyses. RESULTS: In The Netherlands, from a health
care perspective the ICER for trastuzumab for a 55 year old
patient was estimated at €19,463/QALY. From a societal per-
spective the ICER became €14,867. As expected, ICERs improve
with younger age. Sensitivity analyses showed that the ICER was
sensitive to the time horizon and the costs for the metastasic
health state. CONCLUSIONS: Overall the Dutch cost-
effectiveness estimate of trastuzumab for early stage breast
cancer can be well described and is well below the Dutch infor-
mal threshold of €80,000/QALY. For the base case analysis the
probability that the ICER is acceptable for thresholds above
€27.000/QALY is 1, indicating a probability of zero for a wrong
decision. Hence, for thresholds above €27,000 the expected
value of information is zero. This analysis provided an early
cost-effectiveness indication of trastuzumab in the adjuvant
setting in The Netherlands and has led to the provisional reim-
bursement. The transferability assessment is addressed in a sepa-
rate abstract.
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OBJECTIVES: Bevacizumab recently received a revised market-
ing authorisation for use in CRC that states “Bevacizumab in
combination with ﬂuoropyrimidine-based chemotherapy is indi-
cated for treatment of patients with metastatic carcinoma of the
colon or rectum”. This means that bevacizumab can be used in
combination with a wider choice of therapies than previously
allowed. This revised indication was based on the NO16966
phase III trial, which evaluated the efﬁcacy of bevacizumab
in combination with capecitabine + oxaliplatin (XELOX).
METHODS: A health state transition model was constructed to
estimate patient survival, stratiﬁed between progression-free sur-
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vival (PFS) and progressive disease, using a parametric extra-
polation of the NO16966 phase III trial survival data. The
predicted time spent in each health state was weighted using
published CRC utility scores to account for patient quality of life
and to estimate the Quality Adjusted Life Years (QALYs) for
both bevacizumab + XELOX and FOLFOX. One-way sensitivity
analysis was performed in order to evaluate the uncertainty
around the base case estimate of the incremental cost effective-
ness ratio (ICER) for bevacizumab + XELOX compared with
FOLFOX. Uncertainty surrounding the parameters of the model
was evaluated by modifying the costs and parametric survival
assumptions. RESULTS: The base case cost per QALY was esti-
mated to be £25,806. The highest ICER was observed when only
a 2-year time horizon was taken (£35,241); this, however, does
not capture all the costs and beneﬁts of the interventions. The
ICER for the scenario in which 100% of FOLFOX patients did
not require an inpatient stay was £31,669 and decreased to
£14,431 when full sensitivity analysis of the administration costs
was performed. CONCLUSIONS: This sensitivity analysis illus-
trated that the combination of bevacizumab and XELOX dem-
onstrated a stable ICER. Substantial cost savings and health
beneﬁts gain through the use of capecitabine and oxaliplatin in
combination with bevacizumab showed to be a cost-effective
treatment strategy.
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OBJECTIVES: Radiotherapy (RT) with charged particles,
protons and carbon ions (c-ions) offers clinical advantages in
cancer treatment compared to conventional RT with photons,
including better tumor control and/or less side-effects. The costs
of particle therapy (PT) are however, much higher then of the
photon therapy. Therefore, the cost-effectiveness of PT as
opposed to the best current photon therapy was examined.
METHODS: In a cost-effectiveness Markov model the prostate
cancer treatments with (A) c-ions and (B) photons were evalu-
ated. The outcomes were survival, quality adjusted survival and
costs. The therapy effects and quality of life estimates were
derived from the literature. Toxicity of treatment was taken into
account. Direct medical costs were assigned. The RT costs were
based on an extensive cost analysis. The time horizon of the
model was 10 years. The analyses were run for a cohort of 70
year old. The study was performed from the health care per-
spective. RESULTS: The expected total health care costs per
patient over 10 years were: A) €22,880, and B) €13,550. The
expected life years were 8.78 and 8.68, respectively. The differ-
ence in the clinical effects became larger, when quality of life
was accounted for. The quality of life adjusted life years
(QALY’s) were A) 7.82 and B) 7.59. Extra costs per QALY
gained were €40,170 (up to €65,000 in a sensitivity analysis).
CONCLUSIONS: The preliminary results indicate that with a
threshold of €80,000 per QALY, treatment with c-ions is cost-
effective (for age 70). The model will be further adapted. Firstly,
treatment with protons will be included. Secondly, analyses will
be performed for different age and risk categories. Thirdly, the
probability that the different treatment modalities are cost-
effective, given the existing uncertainty, will be assessed. Finally,
an expected value of perfect information (EVPI) analysis will be
conducted.
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OBJECTIVES: Evaluation of costs of oral capecitabine and cis-
platin (XP) treatment vs. intravenous 5FU and cisplatin (FP)
infusion from public payer’s perspective in Poland. METHODS:
Based on systematic review of medical databases similar clinical
efﬁcacy for compared treatment options was proved. Therefore a
cost minimization analysis was performed to identify costs and
estimate potential beneﬁts of 5FU/cisplatin replacement with
capecitabine/cisplatin scheme, from public payer perspective.
Efﬁcacy and safety data were derived from clinical trial published
by Y.Kang et al. (JCO, 2006 ASCO Annual Proceedings). A
pharmacoeconomic model was used to compare costs of these
two therapies. Costs of alternative therapies were estimated
based on clinical results on actual dose and number of adminis-
trations. Clinical experts panel estimated typical treatment pat-
terns and costs of treating major AEs in Poland. RESULTS: Mean
duration of hospitalization in XP arm was 5.11 days and in FP
arm was 22.15 days. The substitution of 5-FU infusion by oral
capecitabine reduced the number of hospitalization days per
cycle. Drug administration costs were signiﬁcantly higher on FP
scheme (8800PLN) in comparison to XP (1515PLN). Total drug
cost per patient on XP scheme was 6384. 41PLN (1 PLN = 3.4
EUR) and 708.20PLN on FP scheme. AE proﬁles were similar.
Total costs (drug, administration and AE) was lower for XP
scheme, generating 1614.12PLN savings per patient/year. Sensi-
tivity analysis was conducted for number of patients treated with
5FU/cisplatin requiring intravenous access and for the drug reim-
bursement level. Reimbursement level doesn’t inﬂuence conclu-
sions drawn from the basic analysis. Change in percentage of
patients requiring intravenous access inﬂuence the conclusions
(breaking point 43%). CONCLUSIONS: Replacing 5FU/
cisplatin scheme with capecitabine/cisplatin in treatment of
advanced gastric cancer patients from public payer in Poland is
cost saving.
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OBJECTIVES: The randomized COST trial revealed no signiﬁ-
cant differences in clinical or quality-of-life endpoints between
LAC and OC for stage I-III colon cancer. We conducted a cost-
minimization analysis from a third-party payer perspective to test
for differences in costs between procedures from surgery through
2 months of follow-up. METHODS: Resource use was collected
on all patients, including: inpatient and ICU days, reoperations,
surgery and anaesthesia times, use of laparotomy and laparo-
scopic instruments, cartridges, reusable and disposable trocars,
and outpatient visits for surgery-related complications. Profes-
sional services were valued based on Medicare reimbursement
rates; all other unit costs were derived from charges adjusted by
ratios-of-costs-to-charges for patients treated at two centers, one
academic (A) and one community (C). 21% of patients assigned
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